Develops drugs for stress-related neuropsychiatric disorders.
Mar 2026Revenue $0.00/yrExpenses $4.50M/yr
No trend
Figures by year
When will Protagenic Therapeutics, Inc.\new be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Mar 2026, revenue was $0.00 and expenses $4.50M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Mar 2026 | $0.00 | $4.50M | −$4.50M |
| Mar 2025 | $0.00 | $2.59M | −$2.59M |
| Dec 2024 | $0.00 | $5.70M | −$5.70M |
| Dec 2023 | $0.00 | $4.53M | −$4.53M |
| Dec 2022 | $0.00 | $3.56M | −$3.56M |
| Dec 2021 | $0.00 | $4.14M | −$4.14M |
| Dec 2020 | $0.00 | $2.55M | −$2.55M |
| Dec 2016 | $0.00 | $2.23M | −$2.23M |
| Dec 2015 | $0.00 | $1.03M | −$1.03M |
| Jun 2014 | $0.00 | $975K | −$975K |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.